138 related articles for article (PubMed ID: 33131089)
1. CXCL10 immunomodulatory effect against infection caused by an antimony refractory isolate of Leishmania braziliensis in mice.
Dutra BM; Rodrigues NLC; Fonseca FRM; de Moura TR; Pacheco de Almeida R; de Jesus AR; Abreu TM; Pompeu MML; Teixeira CR; Teixeira MJ
Parasite Immunol; 2021 Mar; 43(3):e12805. PubMed ID: 33131089
[TBL] [Abstract][Full Text] [Related]
2. BALB/c mice infected with antimony treatment refractory isolate of Leishmania braziliensis present severe lesions due to IL-4 production.
Costa DL; Carregaro V; Lima-Júnior DS; Silva NM; Milanezi CM; Cardoso CR; Giudice Â; de Jesus AR; Carvalho EM; Almeida RP; Silva JS
PLoS Negl Trop Dis; 2011 Mar; 5(3):e965. PubMed ID: 21390155
[TBL] [Abstract][Full Text] [Related]
3. Resistance of Leishmania (Viannia) braziliensis to nitric oxide: correlation with antimony therapy and TNF-alpha production.
Souza AS; Giudice A; Pereira JM; Guimarães LH; de Jesus AR; de Moura TR; Wilson ME; Carvalho EM; Almeida RP
BMC Infect Dis; 2010 Jul; 10():209. PubMed ID: 20633260
[TBL] [Abstract][Full Text] [Related]
4. Intraspecies susceptibility of Leishmania (Viannia) braziliensis to antileishmanial drugs: Antimony resistance in human isolates from atypical lesions.
Rugani JN; Quaresma PF; Gontijo CF; Soares RP; Monte-Neto RL
Biomed Pharmacother; 2018 Dec; 108():1170-1180. PubMed ID: 30372818
[TBL] [Abstract][Full Text] [Related]
5. Molecular epidemiology and in vitro evidence suggest that Leishmania braziliensis strain helps determine antimony response among American tegumenary leishmaniasis patients.
Silva SC; Guimarães LH; Silva JA; Magalhães V; Medina L; Queiroz A; Machado PRL; Schriefer A
Acta Trop; 2018 Feb; 178():34-39. PubMed ID: 29042262
[TBL] [Abstract][Full Text] [Related]
6. Testing of four Leishmania vaccine candidates in a mouse model of infection with Leishmania (Viannia) braziliensis, the main causative agent of cutaneous leishmaniasis in the New World.
Salay G; Dorta ML; Santos NM; Mortara RA; Brodskyn C; Oliveira CI; Barbiéri CL; Rodrigues MM
Clin Vaccine Immunol; 2007 Sep; 14(9):1173-81. PubMed ID: 17626159
[TBL] [Abstract][Full Text] [Related]
7. Impaired Th1 Response Is Associated With Therapeutic Failure in Patients With Cutaneous Leishmaniasis Caused by Leishmania braziliensis.
Carvalho AM; Guimarães LH; Costa R; Saldanha MG; Prates I; Carvalho LP; Arruda S; Carvalho EM
J Infect Dis; 2021 Feb; 223(3):527-535. PubMed ID: 32620011
[TBL] [Abstract][Full Text] [Related]
8. Oral Tolerance Induced by Heat Shock Protein 65-Producing
Guerra PV; Andrade CM; Nunes IV; Gama BC; Tibúrcio R; Santos WLC; Azevedo VA; Tavares NM; Rebouças JS; Maiolii TU; Faria AMC; Brodskyn CI
Front Immunol; 2021; 12():647987. PubMed ID: 34248935
[TBL] [Abstract][Full Text] [Related]
9. S-nitrosoglutathione (GSNO) is cytotoxic to intracellular amastigotes and promotes healing of topically treated Leishmania major or Leishmania braziliensis skin lesions.
Costa IS; de Souza GF; de Oliveira MG; Abrahamsohn Ide A
J Antimicrob Chemother; 2013 Nov; 68(11):2561-8. PubMed ID: 23788476
[TBL] [Abstract][Full Text] [Related]
10. In vitro characterization of Leishmania (Viannia) braziliensis isolates from patients with different responses to Glucantime(®) treatment from Northwest Paraná, Brazil.
Fernandes AC; Pedroso RB; de Mello TF; Donatti L; Venazzi EA; Demarchi IG; Aristides SM; Lonardoni MV; Silveira TG
Exp Parasitol; 2016 Aug; 167():83-93. PubMed ID: 27181585
[TBL] [Abstract][Full Text] [Related]
11. Protection mediated by chemokine CXCL10 in BALB/c mice infected by Leishmania infantum.
Figueiredo WME; Viana SM; Alves DT; Guerra PV; Coêlho ZCB; Barbosa HS; Teixeira MJ
Mem Inst Oswaldo Cruz; 2017 Aug; 112(8):561-568. PubMed ID: 28767981
[TBL] [Abstract][Full Text] [Related]
12. Immunity to Lutzomyia whitmani Saliva Protects against Experimental Leishmania braziliensis Infection.
Gomes R; Cavalcanti K; Teixeira C; Carvalho AM; Mattos PS; Cristal JR; Muniz AC; Miranda JC; de Oliveira CI; Barral A
PLoS Negl Trop Dis; 2016 Nov; 10(11):e0005078. PubMed ID: 27812113
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapeutic potential of 17-AAG against cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis.
Santos DM; Petersen AL; Celes FS; Borges VM; Veras PS; de Oliveira CI
PLoS Negl Trop Dis; 2014 Oct; 8(10):e3275. PubMed ID: 25340794
[TBL] [Abstract][Full Text] [Related]
14. CXCL10 production by human monocytes in response to Leishmania braziliensis infection.
Vargas-Inchaustegui DA; Hogg AE; Tulliano G; Llanos-Cuentas A; Arevalo J; Endsley JJ; Soong L
Infect Immun; 2010 Jan; 78(1):301-8. PubMed ID: 19901067
[TBL] [Abstract][Full Text] [Related]
15. In vitro effect of Bothrops leucurus lectin (BLL) against Leishmania amazonensis and Leishmania braziliensis infection.
Aranda-Souza MÂ; de Lorena VMB; Dos Santos Correia MT; de Figueiredo RCBQ
Int J Biol Macromol; 2018 Dec; 120(Pt A):431-439. PubMed ID: 30118767
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylases inhibitors as new potential drugs against Leishmania braziliensis, the main causative agent of new world tegumentary leishmaniasis.
Ângelo de Souza L; Silva E Bastos M; de Melo Agripino J; Souza Onofre T; Apaza Calla LF; Heimburg T; Ghazy E; Bayer T; Ferraz da Silva VH; Dutra Ribeiro P; Licursi de Oliveira L; Costa Bressan G; de Almeida Lamêgo MR; Silva-Júnior A; de Souza Vasconcellos R; Suarez-Fontes AM; Almeida-Silva J; Vannier-Santos MA; Pierce R; Sippl W; Lopes Rangel Fietto J
Biochem Pharmacol; 2020 Oct; 180():114191. PubMed ID: 32777278
[TBL] [Abstract][Full Text] [Related]
17. CCR2 signaling contributes to the differentiation of protective inflammatory dendritic cells in Leishmania braziliensis infection.
Costa DL; Lima-Júnior DS; Nascimento MS; Sacramento LA; Almeida RP; Carregaro V; Silva JS
J Leukoc Biol; 2016 Aug; 100(2):423-32. PubMed ID: 26884611
[TBL] [Abstract][Full Text] [Related]
18. Morita-Baylis-Hillman adduct shows in vitro activity against Leishmania (Viannia) braziliensis associated with a reduction in IL-6 and IL-10 but independent of nitric oxide.
Amorim FM; Rodrigues YK; Barbosa TP; Néris PL; Caldas JP; Sousa SC; Leite JA; Rodrigues-Mascarenhas S; Vasconcellos ML; Oliveira MR
Parasitology; 2013 Jan; 140(1):29-38. PubMed ID: 22906971
[TBL] [Abstract][Full Text] [Related]
19. Resistance of Leishmania (Leishmania) amazonensis and Leishmania (Viannia) braziliensis to nitric oxide correlates with disease severity in Tegumentary Leishmaniasis.
Giudice A; Camada I; Leopoldo PT; Pereira JM; Riley LW; Wilson ME; Ho JL; de Jesus AR; Carvalho EM; Almeida RP
BMC Infect Dis; 2007 Feb; 7():7. PubMed ID: 17316450
[TBL] [Abstract][Full Text] [Related]
20. Leishmania tarentolae expressing CXCL-10 as an efficient immunotherapy approach against Leishmania major-infected BALB/c mice.
Montakhab-Yeganeh H; Abdossamadi Z; Zahedifard F; Taslimi Y; Badirzadeh A; Saljoughian N; Taheri T; Taghikhani M; Rafati S
Parasite Immunol; 2017 Oct; 39(10):. PubMed ID: 28833211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
